Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07087613
ABSTRACT:
A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.
REFERENCES:
patent: 3800039 (1974-03-01), Marquis et al.
patent: 4139561 (1979-02-01), Onopchenko et al.
patent: 4216341 (1980-08-01), Onopchenko et al.
patent: 4219679 (1980-08-01), Onopchenko et al.
patent: 4255313 (1981-03-01), Antonoplos et al.
patent: 4281127 (1981-07-01), LeMahieu et al.
patent: 4305751 (1981-12-01), Sabourin et al.
patent: 4322420 (1982-03-01), Kobayashi et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 5089499 (1992-02-01), Barker et al.
patent: 5214144 (1993-05-01), Tai et al.
patent: 5256781 (1993-10-01), Primeau et al.
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker
patent: 5580870 (1996-12-01), Barker
patent: 5616582 (1997-04-01), Barker
patent: 5639881 (1997-06-01), Skibo et al.
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5686458 (1997-11-01), Lee et al.
patent: 5707992 (1998-01-01), Webber et al.
patent: 5710145 (1998-01-01), Engel et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5817674 (1998-10-01), Clemence et al.
patent: 5821246 (1998-10-01), Brown et al.
patent: 5948784 (1999-09-01), Fujiwara et al.
patent: 6004967 (1999-12-01), MacMahon et al.
patent: 6004979 (1999-12-01), Clemence et al.
patent: 6130218 (2000-10-01), Morsdorf et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6476040 (2002-11-01), Norris et al.
patent: 6706721 (2004-03-01), Allen et al.
patent: 2002/0061304 (2002-05-01), Miller et al.
patent: 2004/0102463 (2004-05-01), Allen et al.
patent: 1842292 (1992-06-01), None
patent: 3101093 (1993-01-01), None
patent: 3813095 (1995-11-01), None
patent: 2086968 (1992-11-01), None
patent: 20003974 (2001-05-01), None
patent: 2936705 (1979-09-01), None
patent: 0498723 (1992-02-01), None
patent: 0520722 (1992-12-01), None
patent: 0566226 (1993-01-01), None
patent: 0579496 (1994-01-01), None
patent: 0602851 (1994-06-01), None
patent: 0635498 (1995-01-01), None
patent: 0635507 (1995-01-01), None
patent: 0667165 (1995-08-01), None
patent: 0787722 (1997-08-01), None
patent: 0837063 (1998-04-01), None
patent: 1044969 (2000-10-01), None
patent: 6205969 (1985-07-01), None
patent: 1048048 (1987-08-01), None
patent: 5208911 (1992-06-01), None
patent: 7309873 (1992-11-01), None
patent: 6192235 (1993-07-01), None
patent: 8099962 (1993-07-01), None
patent: 7101941 (1993-09-01), None
patent: 6336481 (1993-12-01), None
patent: 7118266 (1994-01-01), None
patent: 0673025 (1994-03-01), None
patent: 7126255 (1994-09-01), None
patent: 8151377 (1994-11-01), None
patent: 7188244 (1995-07-01), None
patent: 9165385 (1995-08-01), None
patent: 9221478 (1997-02-01), None
patent: 10036325 (1998-02-01), None
patent: 10036326 (1998-02-01), None
patent: 0245662 (1993-01-01), None
patent: 2127263 (1993-01-01), None
patent: WO 9220642 (1992-11-01), None
patent: WO 9503283 (1995-02-01), None
patent: WO 9515758 (1995-06-01), None
patent: WO 9609294 (1996-03-01), None
patent: WO 9615118 (1996-05-01), None
patent: WO 9625422 (1996-08-01), None
patent: WO 9628430 (1996-09-01), None
patent: WO 9630347 (1996-10-01), None
patent: WO 9640210 (1996-12-01), None
patent: WO 9703069 (1997-01-01), None
patent: WO 9730035 (1997-08-01), None
patent: WO 9732856 (1997-09-01), None
patent: WO 9738983 (1997-10-01), None
patent: WO 9741896 (1997-11-01), None
patent: WO 9813354 (1998-04-01), None
patent: WO 9903803 (1999-01-01), None
patent: WO 9955683 (1999-11-01), None
patent: WO 9960023 (1999-11-01), None
patent: WO 0031048 (2000-02-01), None
patent: WO 0134574 (2001-05-01), None
patent: WO 0170255 (2001-09-01), None
Agharker, S., et al., “Enhancement of Solubility of Drug Salts by Hydrophilic Counterions: Properties of Organic Salts of an Antimalarial Drug,”Journal of Pharmaceutical Sciences1976, vol. 65, No. 5, pp. 747-749.
Berge, S., et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences1977, vol. 66 No. 1, pp. 1-19.
Bleicher, L., et al., “Aryl- and Hetero-Alkyne Coupling Reactions Catalyzed by Palladium on Carbon and CuI in an Aqueous Medium,”SynlettNov. 1995, pp. 1115-1116.
Bleicher, L., et al., “A Practical and Efficient Synthesis of the Selective Neuronal Acetylcholine-Gated Ion Agonist (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate (SIB-1508Y),”Journal of Organic Chemistry1998, vol. 63, No. 4, pp. 1109-1118.
Botros, S., et al., “Synthesis of Certain Nitro-quinazoline Derivatives Structurally Related to Some Chemotherapeutic Agents,”Egypt. J. Pharm. Sci.1972, vol. 13, No. 1, pp. 11-21.
Cerny, A., “Solvolysis of Some 1-(8a-ergolyinyl)-3,3-Diethylureas and Their Salts,”Collection-Czechoslovak Chem. Commun.1987, vol. 52, pp. 1331-1339.
Draetta, G. et al., Ann. Rep. Med. Chem. (1996) Academic Press, San Diego, pp. 241-246.
Driscoll D. et al., “Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 on Vascular Endothelial Growth Factor Secretion from Several Tumor Models” (1999) XP-001014746 (Abstract only).
Hussain, M., et al., “Parenteral Formulation of the Kappa Agonist Analgesic, DuP 747, via Micellar Solubilization,”Pharmaceutical Research1992, vol. 9, No. 6, pp. 750-752.
Ishiwata T. et al., “Characterization of Keratinocyte Growth Factor and Receptor Expression in Human Pancreatic Cancer” (1998)American Journal of Pathology153(1): 213-222.
Liu N. et al., “Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma” (1998)American Journal of Pathology153(1) 263-269.
Melissaris, A.P. et al., “A Simple and Economical Synthetic Route to p-Ethynylaniline and Ethynyl-Terminated Substrates” (1994) J. Org. Chem. 59: 5818-5821.
Montalbetti, C. et al., “A Convergent Synthesis of Functionalized B-secoTaxane Skeletons” (1995)Tetrahedron Letters36(33): 5891-5894.
Moyer, J., et al., “Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase,”Cancer Research1997, vol. 57, pp. 4838-4848.
Norris, T., et al., “Discovery of a New Stable Polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxy-ethoxy)quinazolinium Methanesulfonate Using Near-Infrared Spectroscopy to Monitor Form Change Kinetics,”J. Chem. Soc., Perkin Trans.2000, vol. 2, pp. 1233-1236.
Norris, T., et al., “Discovery of a New Stable Polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxy-ethoxy)-quinazolinium Methanesulfonate Using Near-Infrared Spectroscopy to Monitor Form Change Kinetics,”J. Chem. Soc., Perkin Trans.2000, vol. 2, pp. 2498-2502.
Onopchenko, et al., “Selective Catalytic Hydrogenation of Aromatic Nitro Groups in the Presence of Acetylenes. Synthesis of (3-Aminophenyl)acetylene via Hydrogenation of Dimethylcarbinol Substituted (3-Nitrophenyl)acetylene over Heterogeneous Metallic Ruthenium Catallyst,”Journal of Organic Chemistry1979, vol. 44, No. 8, pp. 1233-1236.
Pollack, V., et al., “Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice,”Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 291, No. 2, pp. 739-748.
Pollack et al., “Therapy of human Carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects” Proceedings of the Annual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only).
Rosenberg, S., et al., “Studies Directed toward t
Connell Richard D.
Ferrante Karen J.
Foster Barbara A.
Kajiji Shama M.
Morin Michael J.
Lee Shu M.
McKenzie Thomas C.
Nguyen Kim T.
OSI Pharmaceuticals, Inc.
LandOfFree
Treating abnormal cell growth with a stable polymorph of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating abnormal cell growth with a stable polymorph of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating abnormal cell growth with a stable polymorph of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693241